CNS & neurological disorders drug targets最新文献_第8页

Unraveling the Emerging Niche Role of Extracellular Vesicles (EVs) in Traumatic Brain Injury (TBI). 揭示细胞外囊泡 (EVs) 在创伤性脑损伤 (TBI) 中的新作用。

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI: 10.2174/0118715273288155240201065041

Sumel Ashique, Radheshyam Pal, Himanshu Sharma, Neeraj Mishra, Ashish Garg

{"title":"Unraveling the Emerging Niche Role of Extracellular Vesicles (EVs) in Traumatic Brain Injury (TBI).","authors":"Sumel Ashique, Radheshyam Pal, Himanshu Sharma, Neeraj Mishra, Ashish Garg","doi":"10.2174/0118715273288155240201065041","DOIUrl":"10.2174/0118715273288155240201065041","url":null,"abstract":"Extracellular vesicles or exosomes, often known as EVs, have acquired significant attention in the investigations of traumatic brain injury (TBI) and have a distinct advantage in actively researching the fundamental mechanisms underlying various clinical symptoms and diagnosing the wide range of traumatic brain injury cases. The mesenchymal stem cells (MSCs) can produce and release exosomes, which offer therapeutic benefits. Exosomes are tiny membranous vesicles produced by various cellular entities originating from endosomes. Several studies have reported that administering MSC-derived exosomes through intravenous infusions improves neurological recovery and promotes neuroplasticity in rats with traumatic brain damage. The therapeutic advantages of exosomes can be attributed to the microRNAs (miRNAs), which are small non-coding regulatory RNAs that significantly impact the regulation of posttranscriptional genes. Exosome-based therapies, which do not involve cells, have lately gained interest as a potential breakthrough in enhancing neuroplasticity and accelerating neurological recovery for various brain injuries and neurodegenerative diseases. This article explores the benefits and drawbacks of exosome treatment for traumatic brain injury while emphasizing the latest advancements in this field with clinical significance.","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"1357-1370"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139731238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural Compounds as Inhibitors of Aβ Peptide and Tau Aggregation. 天然化合物作为Aβ肽和Tau聚集的抑制剂。

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI: 10.2174/0118715273273539231114095300

Kadja Luana Chagas Monteiro, Thiago Mendonça de Aquino, Edeildo Ferreira da Silva-Júnior

引用次数: 0

Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders. 纳米复合材料和纳米粒子在治疗神经退行性疾病中的应用。

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI: 10.2174/0118715273283338240104112106

Javeria Fatima, Yasir Hasan Siddique

{"title":"Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.","authors":"Javeria Fatima, Yasir Hasan Siddique","doi":"10.2174/0118715273283338240104112106","DOIUrl":"10.2174/0118715273283338240104112106","url":null,"abstract":"Neurodegenerative diseases represent a formidable global health challenge, affecting millions and imposing substantial burdens on healthcare systems worldwide. Conditions, like Alzheimer's, Parkinson's, and Huntington's diseases, among others, share common characteristics, such as neuronal loss, misfolded protein aggregation, and nervous system dysfunction. One of the major obstacles in treating these diseases is the presence of the blood-brain barrier, limiting the delivery of therapeutic agents to the central nervous system. Nanotechnology offers promising solutions to overcome these challenges. In Alzheimer's disease, NPs loaded with various compounds have shown remarkable promise in preventing amyloid-beta (Aβ) aggregation and reducing neurotoxicity. Parkinson's disease benefits from improved dopamine delivery and neuroprotection. Huntington's disease poses its own set of challenges, but nanotechnology continues to offer innovative solutions. The promising developments in nanoparticle-based interventions for neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), have offered new avenues for effective treatment. Nanotechnology represents a promising frontier in biomedical research, offering tailored solutions to the complex challenges posed by neurodegenerative diseases. While much progress has been made, ongoing research is essential to optimize nanomaterial designs, improve targeting, and ensure biocompatibility and safety. Nanomaterials possess unique properties that make them excellent candidates for targeted drug delivery and neuroprotection. They can effectively bypass the blood-brain barrier, opening doors to precise drug delivery strategies. This review explores the extensive research on nanoparticles (NPs) and nanocomposites in diagnosing and treating neurodegenerative disorders. These nanomaterials exhibit exceptional abilities to target neurodegenerative processes and halt disease progression.","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"1217-1233"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139577219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence in The Management of Neurodegenerative Disorders. 神经退行性疾病管理中的人工智能。

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI: 10.2174/0118715273266095231009092603

Sanchit Dhankhar, Somdutt Mujwar, Nitika Garg, Samrat Chauhan, Monika Saini, Prerna Sharma, Suresh Kumar, Satish Kumar Sharma, Mohammad Amjad Kamal, Nidhi Rani

{"title":"Artificial Intelligence in The Management of Neurodegenerative Disorders.","authors":"Sanchit Dhankhar, Somdutt Mujwar, Nitika Garg, Samrat Chauhan, Monika Saini, Prerna Sharma, Suresh Kumar, Satish Kumar Sharma, Mohammad Amjad Kamal, Nidhi Rani","doi":"10.2174/0118715273266095231009092603","DOIUrl":"10.2174/0118715273266095231009092603","url":null,"abstract":"Neurodegenerative disorders are characterized by a gradual but irreversible loss of neurological function. The ability to detect and treat these conditions successfully is crucial for ensuring the best possible quality of life for people who suffer from them. The development of effective new methods for managing and treating neurodegenerative illnesses has been made possible by recent developments in computer technology. In this overview, we take a look at the prospects for applying computational approaches, such as drug design, AI, ML, and DL, to the treatment of neurodegenerative diseases. To review the current state of the field, this article discusses the potential of computational methods for early disease detection, quantifying disease progression, and understanding the underlying biological mechanisms of neurodegenerative diseases, as well as the challenges associated with these approaches and potential future directions. Moreover, it delves into the creation of computational models for the individualization of care for neurodegenerative diseases. The article concludes with suggestions for future studies and clinical applications, highlighting the advantages and disadvantages of using computational techniques in the treatment of neurodegenerative diseases.","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"931-940"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic Disorder Therapeutics and their Effects on Memory. 代谢紊乱的治疗及其对记忆的影响。

CNS & neurological disorders drug targets Pub Date : 2024-01-01 DOI: 10.2174/0118715273269329231013074613

Punita Aggarwal, Faiz Khan, Sugato Banerjee

{"title":"Metabolic Disorder Therapeutics and their Effects on Memory.","authors":"Punita Aggarwal, Faiz Khan, Sugato Banerjee","doi":"10.2174/0118715273269329231013074613","DOIUrl":"10.2174/0118715273269329231013074613","url":null,"abstract":"Diabetes is one of the major metabolic disorders of this era. It not only impacts a person's lifestyle but also has a long-term impact on the brain. It has a detrimental effect on a person's health when combined with hypertension and hyperlipidaemia. Several studies have suggested that the incidence of dementia is higher in people with metabolic syndrome. Investigations are underway to determine whether antidiabetic, hypolipidemic, hypercholesteraemic, anti-hypertensive, and other combination medicines can minimize the incidence of cognitive impairment. Some studies have suggested that anti-diabetic drugs like metformin, liraglutide, and dapagliflozin might enhance memory in long-term users. At the same time, other studies indicate that long-term insulin use may cause memory decline. Similarly, drugs like ACEIs, CCBs, fibrates, statins, and various nutraceuticals have been shown to improve cognition via multiple mechanisms. Literature suggests that drugs that can treat metabolic syndrome can also partially reduce the accumulation of beta-amyloid, whereas some studies contradict these findings. We review the past thirty years' of research work and summarize the effects of most commonly used drugs and nutraceuticals for treating metabolic syndrome on memory. Here, we review the effects of antidiabetic, hypolipidemic, anti-hypertensive, and hypercholesteremic, and their combination in learning and memory.","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"1061-1074"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Resting-State Functional Connectivity of the Default Mode Networks in Patients With Obstructive Sleep Apnea-Hypopnea Syndrome. 阻塞性睡眠呼吸暂停-低通气综合征患者默认模式网络的静息状态功能连接性。

CNS & neurological disorders drug targets Pub Date : 2016-12-19

Ting Chen, Ming Yang, Bin Liu, Yu-Ting Liu, Hui-Xin Zhang, Chuan-Chuan Liu, Yue Zhu, Zhi-Chun Huang, Ti-Fei Yuan

引用次数: 0